Matching patients to personalized cancer therapies is the first step to advancing better cancer care and curbing wasteful spending on suboptimal treatments.

Benefits of CureMatch Include

• Provide cancer patients and oncologists with more accurate, value-based personalized therapy options to consider; each, matched to the patient’s unique molecular profile.

• Identify the most effective cancer drugs and avoid ineffective ones. CureMatch helps identify and stay clear of ineffective treatments, so patients are treated earlier, thereby increasing their chance of a better outcome.  Curbing wasteful spending on ineffective, low-clinical-value treatments in favor of more effective, high-value ones, benefits patients, providers, plan sponsors and employer stop-loss carriers alike.

• Lessen adverse drug event risk by mitigating the chance of avoidably authorizing a potentially dangerous cancer drug.

• Promote ERISA compliance by taking active measures to ensure that plan assets are not improperly spent on cancer treatments that are scientifically known to be ineffective for the subject patient.

• Replace obsolete and misdirected “lowest-net-cost” oncology formulary logic with a solution based on more advanced and accurate “comparative effectiveness analysis”.

Request CureMatch Information For Third-Party Administrators